Week in Review: Shanghai's Zenas Acquires CD19 Antibody from Xenco in $480 Million Deal

Deals and Financings   Zenas, a Shanghai-Boston biopharma, announced a $480 million deal with Xencor for global rights to a bifunctional antibody that targets CD19; Suzhou CStone Pharma out-licensed greater  China  rights for its CTLA-4 mAb to Jiangsu Hengrui Pharma in a $200 million agreement; Changzhou Tongshu Biotechnology raised $78 million in a C round to support its gene testing products for cancer diagnostics; Neurophth Therapeutics, a Wuhan-San Diego ophthalmic gene therapy company, closed a more-than $60 million Series C financing that included  China investors; Allorion of Boston and  Guangzhou  completed a $40 million Series A round to develop next-gen precision medicines for oncology and autoimmune diseases;   Nanjing Simcere Pharma formed a novel antiviral drug collaboration for COVID-19 with the Shanghai Institute of Materia Medica;  News   Beijing 's BeiGene will invest hundreds of millions of dollars to build a biologics manufacturing center on a former Bristol-Myers Squibb site in the  Princeton , NJ area; The two co-founders of the WuXi AppTech/WuXi Biologics CROs, Drs. Ge Li and Ning Zhao, made a $20 million charitable gift to Memorial Sloan Kettering Cancer Center in  New York City  to support cancer research;   Trials and Approvals   3D Medicines was approved to launch its anti-PD-L1 therapy in China , the first subcutaneously administered anti-PD-L1 approved anywhere in the world; Apollomics dosed the first patient in a China Phase III trial of uproleselan to treat relapsed or refractory acute myeloid leukemia.  Stock Symbols: (NSDQ: XNCR) (HK: 2616) (SHA: 600276) (HK: 2096) (NSDQ: BGNE; HK: 06160) Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.